Literature DB >> 18230049

Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species.

Varsha Gupta1.   

Abstract

The multi drug resistant gram negative bacteria especially Pseudomonas aeruginosa and Acinetobacter species are on the rise. The major defense in these bacteria against beta-lactam antibiotics is production of metallo beta lactamases (MBLs) which degrade this group of antibiotics including carbapenems. Till now five main types of MBLs have been described throughout the World--IMP, VIM, SPM, GIM and SIM. A new MBL has been recently reported in P. aeruginosa from Australia--bla AIM-1. There are no standard guidelines by CLSI for detection of these enzymes in various bacteria. A number of phenotypic tests based on different beta lactam-inhibitor combinations are being evaluated and used for routine testing. Regarding the treatment options--colistin, various antibiotic combinations and a few novel antibiotics are being tried and evaluated. Prevention is based on age old practices of strict infection control and judicious use of antibiotics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230049     DOI: 10.1517/13543784.17.2.131

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  24 in total

1.  IMP-29, a novel IMP-type metallo-β-lactamase in Pseudomonas aeruginosa.

Authors:  Katy Jeannot; Laurent Poirel; Marjorie Robert-Nicoud; Pascal Cholley; Patrice Nordmann; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

2.  Rapid detection of carbapenemase-producing Pseudomonas spp.

Authors:  Laurent Dortet; Laurent Poirel; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

3.  Bloodstream infections caused by Pseudomonas spp.: how to detect carbapenemase producers directly from blood cultures.

Authors:  Laurent Dortet; Anne Boulanger; Laurent Poirel; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2014-02-05       Impact factor: 5.948

4.  Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.

Authors:  Cécile Emeraud; Lelia Escaut; Athénaïs Boucly; Nicolas Fortineau; Rémy A Bonnin; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

5.  A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment.

Authors:  Thibaud Boulant; Agnès B Jousset; Rémy A Bonnin; Aurélie Barrail-Tran; Adrien Borgel; Saoussen Oueslati; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-10-21       Impact factor: 5.191

6.  Role of Pseudomonas aeruginosa AmpR on β-lactam and non-β-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics.

Authors:  Hansi Kumari; Deepak Balasubramanian; Diansy Zincke; Kalai Mathee
Journal:  J Med Microbiol       Date:  2014-01-25       Impact factor: 2.472

Review 7.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

8.  Evaluation of phenotypic tests for detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa strains in China.

Authors:  Ting-ting Qu; Jun-li Zhang; Jie Wang; Jing Tao; Yun-song Yu; Ya-gang Chen; Jian-ying Zhou; Lan-juan Li
Journal:  J Clin Microbiol       Date:  2009-02-11       Impact factor: 5.948

9.  Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test.

Authors:  Laurent Dortet; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

10.  Virtual Screening and Experimental Testing of B1 Metallo-β-lactamase Inhibitors.

Authors:  Joon S Kang; Antonia L Zhang; Mohammad Faheem; Charles J Zhang; Ni Ai; John D Buynak; William J Welsh; Peter Oelschlaeger
Journal:  J Chem Inf Model       Date:  2018-08-29       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.